Literature DB >> 23938372

Introduction of staging laparoscopy in the management of advanced epithelial ovarian, tubal and peritoneal cancer: impact on prognosis in a single institution experience.

A Fagotti1, G Vizzielli, F Fanfani, B Costantini, G Ferrandina, V Gallotta, S Gueli Alletti, L Tortorella, G Scambia.   

Abstract

OBJECTIVE: To evaluate the prognostic impact of routinely use of staging laparoscopy (S-LPS) in patients with primary advanced epithelial ovarian cancer (AEOC).
METHODS: All women were submitted to S-LPS before receiving primary debulking surgery (PDS) or neoadjuvant treatment (NACT). The surgical and survival outcome were evaluated by univariate and multivariate analysis.
RESULTS: Among 300 consecutive patients submitted to S-LPS no complications related to the surgical procedure were registered. The laparoscopic evaluation showed that almost half of the patients (46.3%) had a high tumor load. One-hundred forty-eight (49.3%) women were considered suitable for PDS and the remaining 152 (50.7%) were submitted to NACT. The percentages of complete (residual tumor, RT=0) and optimal (RT<1cm) cytoreduction of PDS and interval debulking surgery (IDS) were 62.1% and 57.5%, 22.5% and 27.7%, respectively, p=0.07. The post-operative complications of NACT/IDS group were lower than PDS group (p=0.01). The median progression free survival in women with RT=0 at PDS was 25 months (95% CI, 15.1-34.8), which was statistically significant longer than in all other patients, irrespective of the type of treatment they received (p=0.0001). At multivariate analysis, residual disease (p=0.011) and performance status (p=0.016) maintained an independent association with the PFS.
CONCLUSIONS: Including S-LPS in a tertiary referral center for the management AEOC does not appear to have a negative impact in terms of survival and it may be helpful to individualize the treatment avoiding unnecessary laparotomies and surgical complications.
© 2013.

Entities:  

Keywords:  Carcinosis; Cytoreduction; Laparoscopy; Ovarian cancer

Mesh:

Year:  2013        PMID: 23938372     DOI: 10.1016/j.ygyno.2013.08.005

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  30 in total

Review 1.  Predictors of optimal cytoreduction in patients with newly diagnosed advanced-stage epithelial ovarian cancer: Time to incorporate laparoscopic assessment into the standard of care.

Authors:  Natalia Rodriguez Gómez-Hidalgo; Bertha Alejandra Martinez-Cannon; Alpa M Nick; Karen H Lu; Anil K Sood; Robert L Coleman; Pedro T Ramirez
Journal:  Gynecol Oncol       Date:  2015-03-28       Impact factor: 5.482

2.  Laparoscopic Surgical Algorithm to Triage the Timing of Tumor Reductive Surgery in Advanced Ovarian Cancer.

Authors:  Nicole D Fleming; Alpa M Nick; Robert L Coleman; Shannon N Westin; Pedro T Ramirez; Pamela T Soliman; Bryan Fellman; Larissa A Meyer; Kathleen M Schmeler; Karen H Lu; Anil K Sood
Journal:  Obstet Gynecol       Date:  2018-09       Impact factor: 7.661

Review 3.  Selecting the best strategy of treatment in newly diagnosed advanced-stage ovarian cancer patients.

Authors:  Lucas Minig; Cristina Zorrero; Pablo Padilla Iserte; Andres Poveda
Journal:  World J Methodol       Date:  2015-12-26

Review 4.  Appropriate Recommendations for Surgical Debulking in Stage IV Ovarian Cancer.

Authors:  Jing-Yi Chern; John P Curtin
Journal:  Curr Treat Options Oncol       Date:  2016-01

Review 5.  Can advanced-stage ovarian cancer be cured?

Authors:  Steven Narod
Journal:  Nat Rev Clin Oncol       Date:  2016-01-20       Impact factor: 66.675

6.  Current and Future Status of Laparoscopy in Gynecologic Oncology.

Authors:  S Rimbach; K Neis; E Solomayer; U Ulrich; D Wallwiener
Journal:  Geburtshilfe Frauenheilkd       Date:  2014-09       Impact factor: 2.915

Review 7.  Current Recommendations for Minimally Invasive Surgical Staging in Ovarian Cancer.

Authors:  Anna Fagotti; Federica Perelli; Luigi Pedone; Giovanni Scambia
Journal:  Curr Treat Options Oncol       Date:  2016-01

8.  Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline.

Authors:  Alexi A Wright; Kari Bohlke; Deborah K Armstrong; Michael A Bookman; William A Cliby; Robert L Coleman; Don S Dizon; Joseph J Kash; Larissa A Meyer; Kathleen N Moore; Alexander B Olawaiye; Jessica Oldham; Ritu Salani; Dee Sparacio; William P Tew; Ignace Vergote; Mitchell I Edelson
Journal:  Gynecol Oncol       Date:  2016-08-08       Impact factor: 5.482

9.  Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline.

Authors:  Alexi A Wright; Kari Bohlke; Deborah K Armstrong; Michael A Bookman; William A Cliby; Robert L Coleman; Don S Dizon; Joseph J Kash; Larissa A Meyer; Kathleen N Moore; Alexander B Olawaiye; Jessica Oldham; Ritu Salani; Dee Sparacio; William P Tew; Ignace Vergote; Mitchell I Edelson
Journal:  J Clin Oncol       Date:  2016-08-08       Impact factor: 44.544

10.  Neoadjuvant chemotherapy and primary debulking surgery utilization for advanced-stage ovarian cancer at a comprehensive cancer center.

Authors:  Jennifer J Mueller; Qin C Zhou; Alexia Iasonos; Roisin E O'Cearbhaill; Farah A Alvi; Amr El Haraki; Ane Gerda Zahl Eriksson; Ginger J Gardner; Yukio Sonoda; Douglas A Levine; Carol Aghajanian; Dennis S Chi; Nadeem R Abu-Rustum; Oliver Zivanovic
Journal:  Gynecol Oncol       Date:  2016-01-09       Impact factor: 5.482

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.